Matthias Eiber (@matthiaseiber) 's Twitter Profile
Matthias Eiber

@matthiaseiber

ID: 1488074999546191872

calendar_today31-01-2022 09:01:57

69 Tweet

80 Followers

27 Following

JNM (@journalofnucmed) 's Twitter Profile Photo

Reflections on the demand for PSMA- and SSTR-targeted radiopharmaceutical therapies: Why we were wrong (and why we will be right eventually). ow.ly/T40950UYrU2 #RPTherapy #NuclearMedicine #Theranostics Jeremie Calais Lisa Bodei, MD, PhD Johannes Czernin

UroToday.com (@urotoday) 's Twitter Profile Photo

Response and progression criteria for PSMA PET: Imaging #ProstateCancer outcomes. Wolfgang Fendler, MD Uni Duisburg-Essen @unidue.bsky.social joins Oliver Sartor, MD Mayo Clinic, to discuss the evolving role of PSMA PET imaging in assessing treatment response and progression in prostate cancer. #WatchNow >

PSMA and Beyond Conference (@psmaconference) 's Twitter Profile Photo

ONE WEEK until the 2025 PSMA & Beyond Conference! Space is limited so register soon! If you cannot join us in LA, virtual registration is available for only $50! bit.ly/psmabeyond

ONE WEEK until the 2025 PSMA & Beyond Conference! Space is limited so register soon! If you cannot join us in LA, virtual registration is available for only $50! bit.ly/psmabeyond
Jeremie Calais (@calaisjeremie) 's Twitter Profile Photo

Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. Radiotherapy & Oncology Masatoshi Hotta UCLA sciencedirect.com/science/articl…

Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (&gt; 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. <a href="/RO_GreenJournal/">Radiotherapy & Oncology</a> <a href="/masatoshihotta/">Masatoshi Hotta</a> <a href="/UCLA/">UCLA</a> 
sciencedirect.com/science/articl…
Thomas Hope (@thomashopemd) 's Twitter Profile Photo

Looking forward to seeing everyone at the PSMA & Beyond Conference starting Friday at UCLA. We have sold out all of our in person availability! If you haven’t registered, you can still join virtually (cvent.me/82PXbr).

Looking forward to seeing everyone at the <a href="/PSMAconference/">PSMA & Beyond Conference</a> starting Friday at UCLA. We have sold out all of our in person availability! If you haven’t registered, you can still join virtually (cvent.me/82PXbr).
Thomas Hope (@thomashopemd) 's Twitter Profile Photo

Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the PSMA and Beyond Conference! bit.ly/42lfdlz

SNMMI (@snm_mi) 's Twitter Profile Photo

BIG NEWS! Yesterday the FDA expanded the indication for lutetium-177 vipivotide tetraxetan (Pluvicto), allowing its use before taxane-based chemotherapy. The new approval triples Pluvicto’s eligible patient population. More here: fda.gov/drugs/resource…

BIG NEWS! Yesterday the FDA expanded the indication for lutetium-177 vipivotide tetraxetan (Pluvicto), allowing its use before taxane-based chemotherapy. The new approval triples Pluvicto’s eligible patient population. More here: fda.gov/drugs/resource…
Daniel Metzler (@danielmetzler) 's Twitter Profile Photo

WHAT A FLIGHT! On our first flight today we got to a clean liftoff, 30sec of flight, and didn't blow up the pad in the meantime. Super proud of our team Isar Aerospace

WHAT A FLIGHT!
On our first flight today we got to a clean liftoff, 30sec of flight, and didn't blow up the pad in the meantime.

Super proud of our team <a href="/isaraerospace/">Isar Aerospace</a>
Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication fda.gov/drugs/resource… The U.S. FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer (mCRPC)

European Association of Nuclear Medicine (EANM) (@eanm_nucmed) 's Twitter Profile Photo

The 63rd Annual Meeting of the German Society for Nuclear Medicine (Deutsche Gesellschaft für Nuklearmedizine - DGN) kicked off yesterday in Bremen! 🇩🇪 If you're attending, stop by the EANM desk! 👋

The 63rd Annual Meeting of the German Society for Nuclear Medicine (Deutsche Gesellschaft für Nuklearmedizine - DGN) kicked off yesterday in Bremen! 🇩🇪

If you're attending, stop by the EANM desk! 👋
ProsTIC (@pros_tic) 's Twitter Profile Photo

Huge congratulations to Michael Hofman for receiving the prestigious 2025 The Royal Australasian College of Physicians Eric Sussman Prize, presented for the best contribution to the knowledge of any branch of internal medicine, adult or pediatrics, for his work in prostate theranostics. racp.edu.au/news-and-event…

Huge congratulations to <a href="/DrMHofman/">Michael Hofman</a> for receiving the prestigious 2025 <a href="/TheRACP/">The Royal Australasian College of Physicians</a> Eric Sussman Prize, presented for the best contribution to the knowledge of any branch of internal medicine, adult or pediatrics, for his work in prostate theranostics.

racp.edu.au/news-and-event…
UroToday.com (@urotoday) 's Twitter Profile Photo

How about Lead-212? Presentation by David Pattison, MBBS, MPH, FRACP, highlighting 212Pb as a promising alpha-emitter for PSMA-targeted therapy in #mCRPC—offering potent tumor kill, short-range precision, manageable safety, and even immune activation potential.. #SNMMI25 written

How about Lead-212? Presentation by David Pattison, MBBS, MPH, FRACP, highlighting 212Pb as a promising alpha-emitter for PSMA-targeted therapy in #mCRPC—offering potent tumor kill, short-range precision, manageable safety, and even immune activation potential.. #SNMMI25 written
drhelennadel (@drhelennadel) 's Twitter Profile Photo

@SNMMI25 Dr Andrew Scott gave Henry Wagner lecture and honored Dr Saul Hertz as founder I-131 therapy and the beginning of our Industrial Revolution now occuring in radiopharmaceutical development and theranostics

@SNMMI25
Dr Andrew Scott gave Henry Wagner lecture and honored Dr Saul Hertz as founder I-131 therapy and the beginning of our Industrial Revolution now occuring in radiopharmaceutical development and theranostics
UroToday.com (@urotoday) 's Twitter Profile Photo

Evaluation of PSMA PET/CT derived predictors for treatment response to 177Lu-PSMA-617: Results from The U.S. Expanded-Access Program. Presented by Koichiro Kimura, MD UCLA. #SNMMI25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4ndhjwx #SNMMI2025 SNMMI

Evaluation of PSMA PET/CT derived predictors for treatment response to 177Lu-PSMA-617: Results from The U.S. Expanded-Access Program. Presented by Koichiro Kimura, MD <a href="/UCLA/">UCLA</a>.  #SNMMI25 written coverage by <a href="/zklaassen_md/">Zach Klaassen</a> <a href="/GACancerCenter/">Georgia Cancer Center</a> &gt; bit.ly/4ndhjwx #SNMMI2025 <a href="/SNM_MI/">SNMMI</a>
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality? "Tumor sequestration affects 68Ga-PSMA biodistribution in normal organs. Patients with a very high tumor load showed a significantly lower uptake of 68Ga-PSMA in normal organs, confirming a tumor sink effect. " An

Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?

"Tumor sequestration affects 68Ga-PSMA biodistribution in normal organs. Patients with a very high tumor load showed a significantly lower uptake of 68Ga-PSMA in normal organs, confirming a tumor sink effect. "

An